Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

InMed Pharmaceuticals (INM) Non-Current Assets: 2021-2025

Historic Non-Current Assets for InMed Pharmaceuticals (INM) over the last 4 years, with Sep 2025 value amounting to $2.6 million.

  • InMed Pharmaceuticals' Non-Current Assets fell 19.59% to $2.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.6 million, marking a year-over-year decrease of 19.59%. This contributed to the annual value of $2.7 million for FY2025, which is 13.42% down from last year.
  • As of Q3 2025, InMed Pharmaceuticals' Non-Current Assets stood at $2.6 million, which was down 5.59% from $2.7 million recorded in Q2 2025.
  • In the past 5 years, InMed Pharmaceuticals' Non-Current Assets ranged from a high of $6.9 million in Q4 2021 and a low of $1.4 million during Q3 2021.
  • Moreover, its 3-year median value for Non-Current Assets was $2.9 million (2023), whereas its average is $3.0 million.
  • Data for InMed Pharmaceuticals' Non-Current Assets shows a peak YoY increase of 125.13% (in 2022) and a maximum YoY decrease of 57.81% (in 2022) over the last 5 years.
  • Over the past 5 years, InMed Pharmaceuticals' Non-Current Assets (Quarterly) stood at $6.9 million in 2021, then plummeted by 57.81% to $2.9 million in 2022, then grew by 18.73% to $3.4 million in 2023, then decreased by 11.99% to $3.0 million in 2024, then declined by 19.59% to $2.6 million in 2025.
  • Its Non-Current Assets stands at $2.6 million for Q3 2025, versus $2.7 million for Q2 2025 and $2.9 million for Q1 2025.